43 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
indication. The BLA must also include significant information regarding the manufacturing controls for the product. The novel nature of our product … including the size and nature of the patient population, the proximity of subjects to clinical sites, the eligibility criteria for the trial
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
the manufacturing controls for the product. The novel nature of our product candidates may introduce uncertain, complex, expensive and lengthy … of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of subjects to clinical sites
S-3ASR
EX-4.3
ZYME
Zymeworks Inc.
2 May 24
Automatic shelf registration
4:34pm
as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion
S-3ASR
ZYME
Zymeworks Inc.
2 May 24
Automatic shelf registration
4:34pm
the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase under the purchase contract, and the nature
D
3e788r ux
3 Jan 24
$50.00 mm in equity / options / securities to be acquired, sold $50.00 mm, 2 investors
4:32pm
8-K
EX-10.1
yq6far cr2v8we3bu2
26 Dec 23
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
8:09am
8-K
EX-10.1
75ywpmag1xw9lkx2sg
21 Sep 23
Termination of a Material Definitive Agreement
4:21pm
8-K
EX-10.1
kmaavh0jdciadafscoim
18 May 23
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
8:40am
8-K
EX-10.1
9cz8bu2dhgnwe g8414c
16 May 23
Entry into a Material Definitive Agreement
8:30am